ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,057.22
0.77%
Dow Jones
38,181.55
0.73%
US Dollar vs MXN
17.00724
0.38%
Brent Oil
83.605
0.08%
Bitcoin
59,315.49
1.85%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Noticias

AGEN Agenus Inc

12.54
-0.72 (-5.43%)
Última actualización: 14:38:12
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Agenus Inc AGEN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.72 -5.43% 12.54 14:38:12
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
13.52 12.52 14.04 13.26
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202406:30BWAgenus Regains Compliance with Nasdaq Minimum Bid Price..
24/4/202409:00BWBotensilimab/Balstilimab Data in MSS CRC Selected for the..
23/4/202406:30BWAgenus to Provide First Quarter 2024 Financial Report and..
12/4/202406:30BWAgenus Announces Updated Phase 1 Data and Progress on..
05/4/202415:30BWAgenus Announces Reverse Stock Split of Common Stock
14/3/202406:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/3/202406:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
05/3/202415:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
29/2/202415:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202406:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
26/2/202415:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/2/202406:30BWAgenus to Participate in Leerink Partners Global Biopharma..
15/2/202407:02EDGAR2Form PRE 14A - Other preliminary proxy statements
15/2/202407:00EDGAR2Form 8-K - Current report
15/2/202406:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
14/2/202407:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202406:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
09/2/202416:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202407:00EDGAR2Form 8-K - Current report
31/1/202406:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
22/1/202408:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/1/202406:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
05/1/202415:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/1/202406:30BWAgenus to Participate in B. Riley Healthcare Conference
04/1/202405:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202405:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202405:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202306:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202306:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
08/12/202315:15EDGAR2Form 8-K - Current report
17/11/202315:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202305:30EDGAR2Form 8-K - Current report
07/11/202305:30BWAgenus Reports Third Quarter 2023 Results
26/10/202308:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
22/10/202311:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202303:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
16/10/202316:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202306:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
06/10/202315:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202306:30BWAgenus To Host BOT/BAL Program Update at ESMO 2023
04/10/202316:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202316:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202316:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202315:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
31/8/202316:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202306:30BWAgenus to Participate in September Investor Conferences
23/8/202307:00EDGAR2Form 8-K - Current report
23/8/202307:00BWAgenus Prioritizes Resources to Accelerate Registration and..

Su Consulta Reciente

NASDAQ
AGEN
Agenus
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados